ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,988,369 | -12.7% | 1,031,259 | -1.1% | 0.01% | -9.1% |
| Q2 2023 | $32,044,974 | +88263.4% | 1,042,452 | +3.6% | 0.01% | -15.4% |
| Q1 2023 | $36,265 | -9.7% | 1,006,533 | -1.0% | 0.01% | -18.8% |
| Q4 2022 | $40,182 | -99.9% | 1,016,755 | +2.7% | 0.02% | 0.0% |
| Q3 2022 | $39,784,000 | -3.5% | 990,138 | +1.0% | 0.02% | 0.0% |
| Q2 2022 | $41,222,000 | +15.3% | 980,548 | +6.9% | 0.02% | +33.3% |
| Q1 2022 | $35,743,000 | -1.5% | 917,431 | +0.7% | 0.01% | +9.1% |
| Q4 2021 | $36,302,000 | +1.7% | 910,952 | -7.8% | 0.01% | 0.0% |
| Q3 2021 | $35,689,000 | -27.1% | 987,535 | -17.4% | 0.01% | -26.7% |
| Q2 2021 | $48,978,000 | -6.3% | 1,194,882 | -0.3% | 0.02% | -11.8% |
| Q1 2021 | $52,282,000 | +157.7% | 1,198,587 | +195.7% | 0.02% | +142.9% |
| Q4 2020 | $20,289,000 | +84.1% | 405,378 | +54.7% | 0.01% | +75.0% |
| Q3 2020 | $11,023,000 | – | 261,999 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |